UBS analyst Matthew Weston downgraded Novartis (NVS) to Neutral from Buy with a price target of CHF 104, down from CHF 111. The firm believes the company’s key growth drivers are already reflected in consensus expectations.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Could Moderna’s (MRNA) 65% Stock Plunge Entice a Takeover?
- Novartis initiated with an Underweight at Morgan Stanley
- Novartis agrees to acquire Anthos for up to $3.1B
- Hold Rating for Novartis AG Due to Limited Potential of Abelacimab Despite Acquisition of Anthos Therapeutics
- M&A News: Novartis Seals $3.1B Deal to Acquire Anthos